Background: Variability in hypertrophic cardiomyopathy (HCM) phenotypic expression is not fully explained by underlying sarcomeric gene mutations and a role for genetic modifiers is supported by animal and human studies. Extreme ventricular hypertrophy is a phenotype associated with sudden cardiac death. Because variants in the estrogen pathway are known to be associated with left ventricular mass in the general population, we hypothesized that estrogen pathway variants are associated with wall thickness in HCM.
